A Phase 1/2 Randomized, Observer-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Varicella Zoster Virus in Healthy Individuals Substudy A Supplemental CSR – Final Phase 1 Analysis

A Phase 1/2 Randomized, Observer-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Varicella Zoster Virus in Healthy Individuals Substudy A Supplemental CSR – Final Phase 1 Analysis zhoum55 Tue, 09/29/2026 - 03:47 PF-07911145 (VZV modRNA Vaccine) PF-07911145 (VZV modRNA Vaccine) PHASE I Wed, 01/25/2023 - 12:00 Fri, 09/19/2025 - 12:00 NCT05703607 C5031001 SSA Public Disclosure Synopsis.pdf (193.7 KB) N https://clinicaltrials.gov/study/NCT05703607?term=NCT05703607&viewType=Card&rank=1 C5031001 Substudy A